Publications by authors named "T F Tuglular"
Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had been treated with Pola-BR in the named patient program from March 2018 to April 2021 from 32 centers in Turkey. All patients received up to six cycles of Pola 1.
View Article and Find Full Text PDFData about the timing of autologous stem cell transplantation (ASCT) in peripheral T cell lymphoma (PTCL) are conflicting. We aimed to investigate the impact of the sequence of ASCT on the survival outcomes in patients with PTCL. Analyzes were performed retrospectively in a total of 81 patients, 16 of whom underwent upfront ASCT and 12 received salvage ASCT.
View Article and Find Full Text PDFBackground: In this retrospective cohort of patients with primary, post-polycythemia vera, or post-essential thrombocythemia myelofibrosis, 57 patients with MF who received ruxolitinib for MF-related symptoms or symptomatic splenomegaly were evaluated.
Methods: The median age of the patients in this cohort was approximately 58 years. Of these, there were 33 patients (57.
Article Synopsis
- Paroxysmal nocturnal hemoglobinuria (PNH) is a complex genetic disorder that can lead to serious complications like blood clots, and recent studies show positive results from a treatment called eculizumab.
- In a study of 138 PNH patients treated with eculizumab in Turkey from 2008 to 2018, common symptoms included fatigue and hemoglobinuria, with significant improvements in hemoglobin and lactate dehydrogenase levels noted after seven months of therapy.
- The findings suggest that eculizumab is effective and well-tolerated, with minimal serious adverse events reported among the patients.